Next article Search Articles Instructions for authors  Access Statistics | Citation Manager  
REVIEW ARTICLE  

 Article Access Statistics
    Viewed16827    
    Printed560    
    Emailed24    
    PDF Downloaded1301    
    Comments [Add]    
    Cited by others 16    

Recommend this journal

Sugammadex - A short review and clinical recommendations for the cardiac anesthesiologist


1 Department of Anesthesia, McGill University, Montreal, Canada
2 Department of Anesthesia, Ludwigsburg Hospital, University Heidelberg, Germany

Correspondence Address:
Thomas M Hemmerling
NRG Laboratory, Montreal General Hospital, 1650 Cedar Avenue, Montreal, H3G 1B7
Canada
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0971-9784.69052

Rights and Permissions

Year : 2010  |  Volume : 13  |  Issue : 3  |  Page : 206-216

 

SEARCH
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles

  Article in PDF (589 KB)
Email article
Print Article
Add to My List
This review outlines the basic pharmacodynamic and pharmacokinetic properties of sugammadex for the cardiac anesthesiologist. It describes the different clinical scenarios when sugammadex can be used during cardiac surgery and gives clinical recommendations. Sugammadex is a unique reversal drug that binds a chemical complex with rocuronium and vecuronium, by which the neuromuscular blockade is quickly reversed. It is free of any clinical side-effects and doses of 2 mg/kg or more reliably reverse neuromuscular blockade within 5-15 min, depending on the depth of the neuromuscular blockade. Doses below 2 mg/kg should be avoided at any time because of the inherent risk of recurarization. Sugammadex should not replace good clinical practice - titration of neuromuscular blocking drugs to clinical needs and objective monitoring of neuromuscular blockade in the operating room or intensive care unit. Neuromuscular transmission should be determined in all patients before sugammadex is considered and 5 min after its administration to ensure that extubation is performed with normal neuromuscular transmission.






[FULL TEXT] [PDF]*
 

 

 

 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 
 
 Reader Comments
 Email Alert *
  *
 * Requires registration (Free)
 
 REVIEW ARTICLE
 




1 Department of Anesthesia, McGill University, Montreal, Canada
2 Department of Anesthesia, Ludwigsburg Hospital, University Heidelberg, Germany

Correspondence Address:
Thomas M Hemmerling
NRG Laboratory, Montreal General Hospital, 1650 Cedar Avenue, Montreal, H3G 1B7
Canada
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0971-9784.69052

Rights and Permissions

This review outlines the basic pharmacodynamic and pharmacokinetic properties of sugammadex for the cardiac anesthesiologist. It describes the different clinical scenarios when sugammadex can be used during cardiac surgery and gives clinical recommendations. Sugammadex is a unique reversal drug that binds a chemical complex with rocuronium and vecuronium, by which the neuromuscular blockade is quickly reversed. It is free of any clinical side-effects and doses of 2 mg/kg or more reliably reverse neuromuscular blockade within 5-15 min, depending on the depth of the neuromuscular blockade. Doses below 2 mg/kg should be avoided at any time because of the inherent risk of recurarization. Sugammadex should not replace good clinical practice - titration of neuromuscular blocking drugs to clinical needs and objective monitoring of neuromuscular blockade in the operating room or intensive care unit. Neuromuscular transmission should be determined in all patients before sugammadex is considered and 5 min after its administration to ensure that extubation is performed with normal neuromuscular transmission.






[FULL TEXT] [PDF]*


        
Print this article     Email this article